Crescent Biopharma, Inc.
NASDAQ:CBIOBiotechnology
-$0.49 today
- Market cap
- $482.30M
- Beta
- 1.15
- P/E (TTM)
- -3.3
- EPS (TTM)
- -$5.33
Volume 0.33M
Average 0.28M
CBIO Other Current Liabilities
Short-term obligations not reported separately, such as accrued expenses.
Crescent Biopharma, Inc.NASDAQ: CBIO
Other Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Other current liabilities rises 289.0% from a year ago
Other current liabilities stood at $6.52M at the end of Q1 FY2026, up 289.0% from a year earlier and down 69.7% from the prior quarter. Over 3 fiscal years it compounded at +76.7% a year.
Context
- Other current liabilities amounted to 3.3% of total assets at the end of Q1 FY2026, down 24.7 pp from a year earlier.
- Other current liabilities increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other current liabilities keeps rising in the next quarterly balance sheet after a +289.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 16.36M USD
- Year-over-year change
- +21430.3%
- 4-year CAGR
- +59.9%
| Period | Period end | Other Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 16.36M | +21430.3% |
| FY2024 | 2024-12-31 | 76K | -97.4% |
| FY2023 | 2023-12-31 | 2.96M | -0.1% |
| FY2022 | 2022-12-31 | 2.97M | +18.6% |
| FY2021 | 2021-12-31 | 2.5M | — |
Other Current Liabilities vs competitors
How CBIO compares with its peers on the latest reported figures
- CBIO's Mar 2026 other current liabilities of $6.52M is the 4th highest of the 10 companies compared; the peer median is $1.31M.
- Its year-over-year change of +289.0% is the highest of 8, against a peer median of -20.6%.
- Other current liabilities amounts to 3.3% of total assets for CBIO, versus a peer median of 1.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $18.45M | — | -8.5% | 8.5% | |
| Jun 2026 | $12M | -25.0% | -27.9% | 1.3% | |
| Mar 2026 | $8.02M | — | — | 2.2% | |
| Mar 2026 | $6.52M | +289.0% | +76.7% | 3.3% | |
| Mar 2026 | $3.32M | -65.5% | -0.9% | 2.3% | |
NBPNovaBridge Biosciences | Dec 2025 | $1.31M | +69.6% | -86.6% | 3.5% |
| Sep 2026 | $1.23M | +32.3% | +7.5% | 0.2% | |
| Mar 2026 | $1.19M | -20.6% | +19.9% | 0.6% | |
| Mar 2026 | $509.4K | +61.7% | +18.6% | 0.9% | |
| Sep 2026 | -$11.93M | -141.7% | -15.5% | 1.0% | |
VRXAVeraxa Biotech Holding AG | — | — | — | — | — |
| Peer median (excluding CBIO) | $1.31M | -20.6% | -4.7% | 1.3% | |
Competitors are the stored peer set for CBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 90.25M | 47.87M | 41.79M | 34.77M | 213.19M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 1.35K | 144.02K | 175.82K | 0 | 18M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 0 | 0 | 38K | 1.28M |
| Total Current Assets | 90.79M | 50.71M | 43.79M | 34.8M | 236.66M |
| Property, Plant & Equipment (Net) | 1.95M | 751.17K | 767.83K | 0 | 2.32M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 4.73M |
| Long-term Investments | 0 | 0 | 0 | 0 | 107K |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 1.61M | 344.71K | 757.91K | 813K | (3.51M) |
| Total Non-current Assets | 3.56M | 1.1M | 1.53M | 813K | 3.64M |
| Total Assets | 94.35M | 51.81M | 45.32M | 35.62M | 240.29M |
| Account Payables | 2.11M | 970.19K | 868.12K | 107K | 10M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 4.16M |
| Other Current Liabilities | 2.5M | 2.97M | 2.96M | 76K | 16.36M |
| Total Current Liabilities | 11.82M | 8.88M | 6.84M | 9.61M | 36.07M |
| Long-term Debt | 0 | 0 | 0 | 37.48M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 4M | 0 |
| Total Non-current Liabilities | 918.61K | 0 | 66.84K | 41.48M | 1.21M |
| Total Liabilities | 12.74M | 8.88M | 6.9M | 51.1M | 37.28M |
| Common Stock | 52.31K | 54.38K | 64.39K | 1K | 28K |
| Retained Earnings | (372.9M) | (419.59M) | (456.49M) | (17.87M) | (171.81M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 81.6M | 42.93M | 38.41M | (15.48M) | 203.01M |
| Total Debt | 1.92M | 918.56K | 808.4K | 37.48M | 1.64M |
| Net Debt | (88.33M) | (46.95M) | (40.98M) | 2.72M | (211.55M) |
Crescent Biopharma, Inc.
NASDAQ:CBIO
Intrinsic Alpha fair value
Locked
Current Price
$12.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.